Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients

David Cabrera-Garcia1 · Andrea Miltiades1 · Peter Yim1 · Samantha Parsons1 · Katerina Elisman1 · Mohammad Taghi Mansouri1 · Gebhard Wagener1 · Neil L. Harrison1,2

Received: 3 February 2022 / Revised: 25 July 2022 / Accepted: 1 August 2022 / Published online: 22 August 2022
© Japanese Society of Hematology 2022

Abstract

Severe coronavirus disease-19 (COVID-19) has been associated with fibrin-mediated hypercoagulability and thromboembolic complications. To evaluate potential biomarkers of coagulopathy and disease severity in COVID-19, we measured plasma levels of eight biomarkers potentially associated with coagulation, fibrinolysis, and platelet function in 43 controls and 63 COVID-19 patients, including 47 patients admitted to the intensive care unit (ICU) and 16 non-ICU patients. COVID-19 patients showed significantly elevated levels of fibrinogen, tissue plasminogen activator (t-PA), and its inhibitor plasminogen activation inhibitor 1 (PAI-1), as well as ST2 (the receptor for interleukin-33) and von Willebrand factor (vWF) compared to the control group. We found that higher levels of t-PA, ST2, and vWF at the time of admission were associated with lower survival rates, and that thrombotic events were more frequent in patients with initial higher levels of vWF. These results support a predictive role of specific biomarkers such as t-PA and vWF in the pathophysiology of COVID-19. The data provide support for the case that hypercoagulability in COVID-19 is fibrin-mediated, but also highlights the important role that vWF may play in the genesis of thromboses in the pathophysiology of COVID-19. Interventions designed to enhance fibrinolysis might prove to be useful adjuncts in the treatment of coagulopathy in a subset of COVID-19 patients.

Keywords Coagulopathy · Fibrinolysis · PAI-1 · vWF · ST2 · COVID-19

Introduction

COVID-19, the disease associated with infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can cause upper respiratory tract (URT) infections that may progress to bilateral pneumonia and acute respiratory distress syndrome (ARDS) [1]. Extra-pulmonary symptoms are also a characteristic of patients with severe COVID-19, and these include systemic inflammation and cytokine release [2], often combined with disorders of blood clotting and secondary manifestations of disease in the lung, kidney, brain, heart, and liver [3]. Increased incidence of thrombosis and thrombotic complications have been widely associated with COVID-19 [4, 5]. Changes in conventional coagulation parameters such as international normalized ratio (INR), d-dimer, and platelet counts may be useful for the rapid detection of hypercoagulation in COVID-19 patients [6], but these parameters do not fully describe the complex biology associated with COVID-19-associated coagulopathy [7].

Our clinical observations of increased thromboembolic complications in COVID-19 led us to use rotational thromboelastometry (ROTEM) to study the mechanisms of hypercoagulability in severe COVID-19. We found that there was a significant increase of fibrin-mediated clot viscosity [8], but the exact mechanism of this fibrin-mediated hypercoagulability has remained elusive. Understanding of the pathogenesis of coagulopathy in COVID-19 is incomplete, and treatment with anticoagulants such as heparin...
in severe COVID-19 patients has been used with mixed results [9]. We hypothesized that coagulopathy associated with severe COVID-19 might be associated with deficits in fibrinolysis, as well as with alterations in the primary coagulation pathway and platelet factors. We designed a study to measure selected coagulation-related biomarkers in plasma from patients with mild and severe COVID-19, admitted between April 2020 and April 2021.

**Patients and methods**

**Patients**

We conducted a prospective cohort study that was approved by Columbia University IRB (protocol #AAAS0172). Sixty-three patients with COVID-19 and 43 controls without COVID-19 were enrolled. COVID-19 status was confirmed by standard reverse transcription-polymerase chain reaction (RT-PCR) test for SARS-CoV-2. 47 of the COVID-19 patient group had symptoms of critical illness (severe infection, respiratory distress, shock, and/or multiorgan dysfunction), requiring admission to the intensive care unit (ICU), while the remaining 16 COVID-19 patients (non-ICU) were admitted to a non-acute hospital bed. All COVID-19 patients with a clinical diagnosis of any of the following: Deep vein thrombosis (DVT), stroke, pulmonary embolism (PE), blood clots in extracorporeal membrane oxygenation (ECMO) or dialysis tubing were defined as thrombotic events. Mortality was determined at the conclusion of this study (September 2021). The control patient group consisted of healthy volunteers and admitted surgical patients with no clinical evidence of viral infection and a negative RT-PCR test within 5 days of sample collection. Informed consent was provided by the patients or the surrogates and blood was drawn. Blood of the same-day surgical patients was drawn prior to the beginning of the surgical procedure. Volunteers were not remunerated for participating in the study and health status of the volunteers was determined by self-report. The study was performed at Columbia University Irving Medical Center in New York, N.Y., and COVID-19 patients and controls were recruited in two phases during April–May 2020, and between November 2020 and April 2021. Blood was drawn into EDTA-containing tubes, rapidly centrifuged and plasma separated before being stored at − 80 °C until analysis. Samples from COVID-19 patients were collected between 5 and 15 days following admission to the ICU. No solvents or detergents were added to the plasma samples, which were handled in a biological safety cabinet under enhanced Bio Safety Level 2 (BSL-2) protocols.

**Enzyme-linked immunosorbent assay (ELISA)**

ELISA kits with colorimetric output were used to determine the plasma concentrations of PAI-1 (ab184863, Abcam), fibrinogen (ab241383, Abcam), plasminogen (ab108893, Abcam), tissue plasminogen activator (t-PA) (ab190812, Abcam), platelet factor 4 (PF4) (ab189573, Abcam), interleukin (IL) 1 receptor-like 1 (ST2) (ab254505, Abcam), von Willebrand factor (vWF) (ab223864, Abcam), and tryptase (EKU10581, Biomatik) according to the manufacturer’s instructions. The plates were read at 450 nm using an automated microplate reader (Biotek Epoch). For each subject, we report the mean value from at least two replicate determinations with a coefficient of variation (CV) lower than 20%. The mean intra-assay CV was lower than 10% for all biomarkers and the inter-assay CVs were 11% for PAI-1, 10% for fibrinogen, 7% for plasminogen, 8% for t-PA, 9% for PF4, 14% for ST2, 10% for vWF, and 12% for tryptase. The plasma concentrations of each biomarker were determined using a standard curve, constructed and fit using a 4P logistic regression equation, and the assay values were corrected by the appropriate dilution factor in each case.

**Statistics**

All statistical analyses were performed using Prism 8 (GraphPad Software, Inc). Comparisons between the different COVID-19 and control groups were performed using Fisher’s test (categorical variables) or the non-parametric Mann–Whitney or Kruskal–Wallis tests (continuous variables). Blood levels of the biomarkers investigated are presented here as population medians, together with either the 95% confidence interval (CI) or the interquartile range (IQR). The sensitivity, sensibility, and area under the curve (AUC) were calculated from the receiver operator characteristics (ROC) curves to estimate the accuracy of each of four selected biomarkers as predictors of mortality and thrombosis. A multivariate logistic regression model was used to analyze the association of all selected biomarkers and the outcomes of mortality and thrombosis. For the logistic regression analysis, ROC curves were performed, and AUC and odds-ratio values are reported. Exact P values (P) are reported and P < 0.05 was considered statistically significant. Additional detailed statistical information is presented in the respective Figure Legends.
Results

Demographics and clinical characteristics

Sixty-three patients (36 males and 27 females, median age 60, IQR 55–69 years) hospitalized with COVID-19 were included in this study. In addition, we recruited 43 controls (20 males and 23 females), median age 45 (IQR 30–61) years. The COVID-19 patients included 47 patients admitted to the ICU (severe COVID-19) and 16 hospitalized patients not requiring ICU admission.

The clinical characteristics of COVID-19 patients are listed in Table 1. No differences were found between the ICU and non-ICU COVID-19 patients in demographics or the prevalence of co-morbidities such as obesity or hypertension (Table 1). Medications given to each COVID-19 group are also reported in Table 1. At the time of blood collection, 46 of 47 (97.9%) ICU patients and 1 of 16 non-ICU patients were mechanically ventilated. Thrombotic events, including stroke, were more common in ICU than in non-ICU patients (44.7 vs 12.5%, respectively). Similarly, a higher percentage of patients (74.5%) with acute kidney injury (AKI) was reported in ICU patients, and 19 ICU patients required continuous renal replacement therapy (CRRT). At the conclusion of this study (September 2021), 17 patients (27.0%) had died and the remainder of the patients, 46 (73.0%), were discharged.

In Table 2, we report selected laboratory values for COVID-19 patients. As reported by others [18], levels of

Table 1 Clinical characteristics of COVID-19 patients

|                     | Total | Non-ICU | ICU | P value |
|---------------------|-------|---------|-----|---------|
| **Demographics**    |       |         |     |         |
| Subjects            | 63    | 16      | 47  | –       |
| Female              | 27(42.8) | 8(50.0) | 19(40.4) | 0.5665 |
| Age (median, years)*| 63(60*) | 16(59*) | 47(61*) | 0.9346 |
| **Comorbidities**   |       |         |     |         |
| Obesity (BMI > 30 kg/m²) | 28(44.4) | 6(37.5) | 22(46.8) | 0.5663 |
| Hypertension        | 37(58.7) | 7(43.7) | 30(63.8) | 0.2397 |
| Diabetes            | 29(46.0) | 5(31.2) | 24(51.1) | 0.2468 |
| Chronic kidney disease | 9(14.2) | 1(6.2) | 8(17.0) | 0.4271 |
| Immuno-compromised  | 9(14.2) | 1(6.2) | 8(17.0) | 0.4271 |
| Heart diseases      | 8(12.6) | 1(6.2) | 7(14.9) | 0.6673 |
| Lung diseases       | 8(12.6) | 5(31.2) | 3(6.4) | 0.0277 |
| **In-hospital medications** |   |         |     |         |
| Steroids            | 44(69.8) | 15(93.7) | 29(61.1) | 0.0247 |
| Broad spectrum antibiotics | 50(79.3) | 7(43.7) | 43(91.4) | 0.0002 |
| Azithromycin        | 37(58.8) | 5(31.2) | 32(68.1) | 0.0173 |
| Hydroxychloroquine  | 32(50.8) | 0(0.0) | 32(68.1) | < 0.0001 |
| Remdesivir          | 20(31.7) | 10(62.5) | 10(21.3) | 0.0043 |
| IL-6 antibodies     | 14(22.2) | 0(0.0) | 14(29.8) | 0.0133 |
| Anticoagulants      | 16(25.4) | 4(25.0) | 12(25.5) | 0.9999 |
| **Clinical outcomes** |       |         |     |         |
| Ventilation         | 46(73.0) | 0(0.0) | 46(97.9) | < 0.0001 |
| Acute kidney injury (AKI) | 40(63.9) | 5(31.2) | 35(74.5) | 0.0030 |
| AKI stage 1         | 12(19.0) | 5(31.2) | 7(14.9) | 0.1623 |
| AKI stage 2         | 4(6.9) | 0(0.0) | 4(8.5) | 0.5645 |
| AKI stage 3         | 24(38.1) | 0(0.0) | 24(51.1) | 0.0002 |
| Thrombotic events   | 23(36.5) | 2(12.5) | 21(44.7) | 0.0355 |
| CRRT                | 19(30.2) | 0(0.0) | 19(40.4) | 0.0014 |
| Deceased            | 17(26.9) | 1(6.2) | 16(34.0) | 0.0479 |

Steroids received include dexamethasone, hydrocortisone, and/or methylprednisolone. IL-6 antibodies: Sarilumab (Kevzara) or tocilizumab (Actemra). Heart diseases include coronary artery disease and congestive heart failure. Ventilation status is reported at the time of blood collection. P values are for non-ICU compared to ICU patients (Mann Whitney or Fisher's test). Values in bold are P < 0.05
d-dimer were significantly elevated in ICU patients [IQR 2.0–11.5 mg/L]. d-Dimer levels were higher in the group of patients admitted to the ICU than in non-ICU patients (\(P < 0.0001\)). Levels of bilirubin and serum creatinine were also higher in the ICU group.

**Coagulation and fibrinolysis markers in mild and severe COVID-19 patients**

We measured the levels of fibrinogen, plasminogen, PAI-1, and t-PA in the plasma of the 63 COVID-19 patients and 43 controls (Fig. 1) to assess the state of the coagulation and fibrinolytic systems. Fibrinogen levels in patients with non-ICU and ICU COVID-19 groups were significantly higher than in the control group (Control vs non-ICU: \(P < 0.0001\), Control vs ICU: \(P < 0.0001\)) (Fig. 1a). No difference was found in plasminogen levels between controls and COVID-19 patients (Fig. 1b), but levels of t-PA were significantly higher in both COVID-19 groups compared to controls (Controls: 4.0 ng/mL vs non-ICU COVID-19: 12.5 ng/mL; \(P < 0.0001\), and vs ICU COVID-19: 22.3 ng/mL; \(P < 0.0001\)) Fig. 1c). In addition, PAI-1 levels were elevated in ICU COVID-19 patients (Fig. 1d).

**Mast cell, T cell, and platelet-related factors in mild and severe COVID-19 patients**

We also investigated the levels of ST2 (the receptor for interleukin-33) to assess the possible involvement of a variety of lymphocytes, including T cells [10], as well as the levels of trypsin as an index of recent mast cell degranulation [11]. Increased levels of ST2 were found in both groups of COVID-19 patients (\(P < 0.0001\) for each group compared to controls), (Fig. 2a). We observed somewhat lower levels of trypsin in the ICU COVID-19 group (Fig. 2b). Finally, we measured the levels of vWF, a marker of endothelial damage and platelet adhesion [12], and the platelet activity factor PF4. Plasma levels of PF4 were similar in COVID-19 groups and controls (Fig. 2d), but the levels of vWF were substantially elevated in both non-ICU and ICU COVID-19 groups (Controls: IQR 6.6–11.9 µg/mL vs non-ICU COVID-19: IQR 19.4–30 ng/mL; \(P = 0.0004\), and vs ICU COVID-19: IQR 28.4–58.2 ng/mL; \(P < 0.0001\)) (Fig. 2c).

We compared the plasma levels of these biomarkers with normal clinical ranges (dotted line in Figs. 1a, c, d, 2a, c, respectively) and found that the majority of COVID-19 patients exhibited levels above the consensus normal range for fibrinogen (> 4 mg/mL: 94% of non-ICU and 87% of ICU patients), t-PA (> 10 ng/mL: 62% of non-ICU and 83% of ICU patients), PAI-1 (> 50 ng/mL: 50% of non-ICU and 72% of ICU patients), ST2 (> 50 ng/mL: 44% of non-ICU and 63% of ICU patients), and vWF (> 10 µg/mL: 100% non-ICU and 92% of ICU patients).

**High levels of t-PA, ST2, and vWF were associated with worse clinical outcomes in severe COVID-19**

To investigate the predictive role of selected biomarkers (PAI-1, t-PA, vWF, and ST2), we asked whether there were any associations between the plasma levels of the biomarkers in COVID-19 patients at admission and two specific clinical outcomes (Fig. 3). High levels of vWF were associated with thrombotic episodes (Fig. 3d), which were more frequent among ICU patients (Table 1, Fig. 3). Levels of vWF were...
Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients

also higher among COVID-19 patients diagnosed with DVT (Fig. S1a–d), which has a high prevalence in COVID-19 [13]. Furthermore, higher levels of t-PA, ST2, and vWF at the time of admission were associated with lower likelihood of survival in COVID-19 patients (Fig. 3f–g). In addition, we found that patients diagnosed with acute kidney injury (AKI) showed higher levels of t-PA and PAI-1 at the time of admission (Fig. S1e–h).

Finally, the areas under the curve (AUCs) were calculated for the same selected biomarkers to evaluate the biomarkers associated with the prognosis of mortality and thrombosis (Fig. 4). At the time of admission, the plasma levels of ST2

**Fig. 1** Plasma levels of fibrinogen, PAI-1, and t-PA are elevated in COVID-19 patients. Fibrinogen (a), plasminogen (b), PAI-1 (c), t-PA (d) were measured in plasma samples from controls (n=43), non-ICU COVID-19 patients (n=16) and ICU COVID-19 patients (n=47). Graphs show individual values with the median and 95% confidence intervals. Deceased patients are indicated as filled symbols. Groups were compared using the Kruskal–Wallis test and P values are shown in each panel. Significant differences (P<0.05) are in bold. The dotted lines represent the upper bound of the normal range for plasma levels of fibrinogen (4 mg/mL) (a), plasminogen (250 μg/mL) (b), PAI-1 (50 ng/mL) (c), and t-PA (10 ng/mL) (d).

**Fig. 2** Plasma levels of ST2 and vWF are elevated in COVID-19 patients. ST2 (a), tryptase (b), vWF (c), and PF4 (d) were measured in plasma samples from control (n=43), non-ICU COVID-19 (n=16), and ICU COVID-19 patients (n=47, n=45 for b–d). Graphs show individual values with the median and 95% confidence intervals. Deceased patients are indicated with filled symbols. Groups were compared using the Kruskal–Wallis test and P values are shown in each panel. Significant differences (P<0.05) are in bold. The dotted lines represent the upper bound of the normal range for plasma levels of ST2 (50 ng/mL) (a) and vWF (10 μg/mL) (d).
(AUC of 0.719, \( P = 0.0096 \)) and vWF (AUC of 0.690, \( P = 0.0252 \)) had acceptable accuracy for the prognosis of mortality (Fig. 4a), whereas vWF showed also fair accuracy (AUC of 0.724, \( P = 0.0035 \)) for the prognosis of thrombotic events (Fig. 4b). The combination of the selected biomarkers (t-PA, PAI-1, vWF, and ST2) using a multivariate logistic regression model yielded similar acceptable accuracy for the prognosis of thrombosis (AUC of 0.7597, \( P = 0.0007 \)) and mortality (AUC of 0.7375, \( P = 0.0051 \)) (Fig. S2).

**Discussion**

Our study demonstrated that ICU patients with COVID-19 have elevated levels of PAI-1, t-PA, and fibrinogen, as well as vWF and the IL-33 receptor, ST2, compared to controls; these findings can explain the frequent observation of fibrin-mediated hypercoagulability and thrombosis in severe COVID-19.

There is normally a homeostatic equilibrium between coagulation and fibrinolysis. Excessive fibrinolysis can result in abnormal bleeding, whereas a deficit in fibrinolysis can result in plaque formation, disseminated intravascular coagulopathy, stroke, and thrombosis [14]. Coagulopathy in COVID-19 has a distinctive pathophysiology that appears to include not only impaired fibrinolysis but also platelet aggregation, inflammation, and microthrombi [15]. Identification and validation of such biomarkers for the prognosis of thrombotic risk in COVID-19 patients is an important and ongoing debate [16]. Evaluation of additional biomarkers studied here such as ST2 and vWF may help to characterize the COVID-19-associated coagulopathy and to identify patients at risk for worse clinical outcomes.
We measured elevated levels of fibrinogen and d-dimer in COVID-19 patients, as reported in similar studies [17, 18], and these results are completely consistent with our prior observations on the important contribution of fibrinogen to the significant increase in clot viscosity in severe COVID-19 [8]. Increased production of fibrinogen, but not plasminogen, may also reflect the increase of extra-hepatically synthesis of fibrinogen in response to inflammation [19]. Together with elevated levels of fibrinogen and d-dimer, a “fibrinolysis shutdown” might also be a characteristic of severe cases of COVID-19, as proposed by previous authors [20].

One of the most important inhibitors of this fibrinolytic system is PAI-1 [21], and elevated levels of PAI-1 have been shown to increase the risk of atherothrombotic events [22]. Our observation of increased PAI-1 levels in COVID-19 further supports the hypothesis that reduced fibrinolysis caused by underproduction of plasmin may contribute to the hypercoagulability in COVID-19. In agreement with others [17, 23], we also found an increase in t-PA levels, the enzyme responsible for the conversion of plasminogen into plasmin, in COVID-19 patients. This may lead to an increase in the rare but serious cases of bleeding in some patients [23]. However, elevated plasma levels of antigen t-PA can be compatible with impaired fibrinolysis when PAI-1 levels are also elevated, because circulating PAI-1 binds rapidly to t-PA, whereas the clearance of active t-PA is faster than the PAI-1/t-PA complexes [24, 25]. Therefore, levels of t-PA are highly correlated with the complex PAI-1/t-PA (inactive t-PA), and high t-PA and PAI-1 levels in COVID-19 patients may indicate a reduction in fibrinolysis. In addition, very high t-PA levels were clearly associated with non-survival in our study.

PAI-1, like t-PA, is normally produced and released from the vascular endothelium, but PAI-1 can also be produced by extravascular tissues, where its expression can be induced via activation of Nuclear Factor κB (NF-κB) by IL-6, Tumor necrosis factor α (TNF α) and a wide range of other pro-inflammatory mediators [21]. These mediators are known as components of the proposed cytokine storm syndrome that is the characteristic of many patients with severe COVID-19 [2].

The IL-33 acts on its cognate receptor ST2 and the IL-33/ST2 axis has been suggested to play a key role in the cytokine storm reported in COVID-19 [10]. We found high concentrations of ST2 in the plasma of COVID-19 patients, which has been suggested to be related to endothelial or pneumonia inflammation and damage [10]. We found that higher levels of ST2 were associated with mortality, which supports the prognostic value of this biomarker in COVID-19, as suggested elsewhere [26].

Mast cells can play a role in the recruitment of inflammatory cells during vascular injury [27] and the production of PAI-1 [28]. Tryptase is generally measured as a proxy indicator of mast cell degranulation [11]. We did not find increases in tryptase in COVID-19 patients, but the involvement of mast cell degranulation in early stages of COVID-19 cannot be completely discarded, since tryptase has a short half-life of 2 h and may trigger other factors involved in degranulation such as IL-6 [11]. Nevertheless, tryptase does not seem likely to be a useful biomarker.
It has been suggested that the association between inflammation and thrombosis in COVID-19 might be mediated by endothelial injury and platelet aggregation [12]. The high levels of vWF found in the plasma of COVID-19 patients confirm similar results from recent studies [29, 30]. These results might reflect an alteration in the balance of vWF and the protease ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin 1 repeats, number 13) that cleaves the vWF multimers released after endothelial damage [30, 31]. The increased level of vWF, which mediates the interaction between platelets and activated endothelium [32], might lead to platelet aggregation and a higher risk of microthrombi [12, 31]. The association of high levels of vWF with thrombosis in our study would seem to support this hypothesis, although the platelet count in non-ICU and ICU COVID-19 groups were in the normal range. Thus, additional markers such as ADAMTS13 as well as the activity of vWF may be required to fully characterize the functional role of vWF during platelet aggregation [33].

Direct or indirect endothelial damage by SARS-CoV-2 and dysregulation of fibrinolysis have been suggested as additional mechanisms related to COVID-19 coagulopathy [7], and vWF may be a part of an endothelium-mediated inflammatory response, along with PAI-1, which may lead to worse clinical outcomes and survival rate, as seen in our study. Our results also suggest the good prognostic value of vWF for severe clinical outcomes in COVID-19.

In contrast to vWF, plasma levels of platelet activity marker PF4 and platelet count were not elevated in our cohort of patients. Although we cannot rule out the possibility of in vitro platelet activation due to the use of EDTA-plasma and sample handling variability [34], the levels of PF4 in COVID-19 patients were lower than or consistent with previous studies [35]. Differences in PF4 levels found in our study among COVID-19 patients might be due to the fast turnover of this biomarker in plasma [36] in contrast to the steady high levels of vWF [37]. Other platelet biomarkers like the platelet receptor P-selectin may be more tightly correlated with the levels of vWF [38]. It has been shown that the levels of P-selectin were elevated only in critically ill COVID-19 patients [39], whereas both P-selectin and soluble CD40 ligand (an activation marker of platelets) seem to contribute to a higher risk of mortality in COVID-19 [40]. Additionally, activation of the complement system, mainly via the membrane attack complex (C5b-9), can also promote platelet adhesion in COVID-19 by inducing the expression of P-selectin and vWF [41].

From the early stages of the COVID-19 pandemic, there have been attempts to rectify the complications associated with COVID-19 coagulopathy by stimulating fibrinolysis, with the initial focus exclusively on t-PA [42]. Recent results from a clinical trial of alteplase showed no bleeding events associated with the treatment but only a slight improvement in oxygenation [43]. It seems unlikely that the use of t-PA would be useful in COVID-19 patients with elevated levels of t-PA, as shown here and by others [23], potentially exposing these patients to excessive bleeding risk. Determining levels of t-PA and PAI-1 and calculating the ratio between t-PA and PAI-1 may help to some degree in identifying patients at risk for bleeding. Furthermore, t-PA administered exogenously has a short half-life [44] and its administration in severe COVID-19 patients would likely result in rapid inactivation, due to the very high levels of ambient PAI-1. There is evidence that streptokinase administered via a nebulizer can be effective in treating coagulopathy in ARDS resulting from other diseases [45] and it might be considered as a useful alternative treatment for COVID-19 coagulopathy.

A primary excess of PAI-1 may contribute to an imbalance between coagulation and fibrinolysis, resulting in the widespread and persistent coagulopathy seen in some COVID-19 patients. Inhibitors of PAI-1 such as tipiloxatin (PAI-039) [46] or the novel TMS5484 [47] are being studied as an intervention in COVID-19, supplementing the use of anticoagulants and corticosteroids. Measuring PAI-1 and t-PA levels, in addition to close monitoring for bleeding complications, would be required to assure safe use of any of these drugs. Other treatments related to the biomarkers measured in this study include anti-ST2 [10] and anti-vWF antibodies [48], but, to the best of our knowledge, clinical trials in COVID-19 are not yet underway.

Our study has some obvious limitations, such as the modest sample size and the use of a single time point for measurement of the biomarkers. For instance, moderate sample sizes may affect the performance of the multivariate logistic regression analysis [49]. Another limitation of our study is that the COVID-19 group was older than the control group and we cannot discard a potential modest effect of age-related differences in some biomarkers such as PAI-1 [21]. In addition, we suspect that the incidence of thrombosis might be underestimated due to the difficulties in the diagnosis of certain thrombotic events such as microthrombosis [50]. There have been some changes in medication regimens given to patients between the initial and subsequent waves of COVID-19, and these might have some effect on the plasma levels of the biomarkers measured in this study. Nevertheless, the reproducible nature of our findings and those of others with respect to PAI-1 [17, 23] and vWF [30, 31] supports the idea that high plasma levels of these biomarkers are a consistent feature of severe COVID-19.

Our study provides strong evidence that elevated levels of certain biomarkers such as t-PA, ST2, and vWF, as well as abnormal coagulation [8], may be related to the incidence of thrombosis, renal failure, and might contribute to other longer term complications in COVID-19 patients. These biomarkers show robust and consistent increases in COVID-19...
and can be assessed at the time of admission to non-ICU and ICU settings; our analysis suggests that they may prove useful as additional predictors of COVID-19 patients at elevated risk for thrombosis or severe clinical outcomes.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s12185-022-03437-2.

**Acknowledgements** This work was supported solely by the Department of Anesthesiology at Columbia University Irving Medical Center (CUIMC). We are grateful to M. Shelanski and A. Brambrink for logistical support of our laboratories during the pandemic, and to C.W. Emala for many helpful discussions. We are deeply grateful to the patients and their families for their participation in this study.

**Author contributions** NLH, GW, PY and DCG: conceived the study and designed the experiments, AM, KE and GW: recruited and consented patients. SP, KE, PY and AM: retrieved patient data. GW, KE, DCG, NLH and MM: processed samples, and DCG: performed the ELISA experiments and data analysis. All authors contributed to data analysis and interpretation. NLH, DCG and GW: wrote the first draft of the manuscript and all authors commented on and edited the manuscript.

**Data availability** All data are available from the corresponding authors upon reasonable request.

**Declarations**

**Conflict of interest** The authors declare no competing financial interests.

**References**

1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.

2. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–43.

3. Gavriatopoulou M, Korompi E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kadristis E, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20:493–506.

4. Bikkedi B, Madhavan MV, Jimenez D, Chuiich T, Dreyfus I, Driggan E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75:2950–73.

5. Klok FA, Kruij MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.

6. Polimeni A, Kim KE, Spaccarotella C, Mongiardo A, Sorrentino S, Sabatino J, et al. Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients. Sci Rep. 2021;11:10464.

7. Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasch Med. 2020;25:471–8.

8. Roh DJ, Eiseman K, Kirsch H, Yoh N, Boehme A, Agrawal S, et al. Brief report: hypercoagulable viscoelastic blood clot characteristics in critically-ill COVID-19 patients and associations with thrombotic complications. J Trauma Acute Care Surg. 2020;90:e7–12.

9. Goligher EC, Bradbury CA, McVerry BJ, REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385:777–89.

10. Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the achilles heel of COVID-19? Lancet Rheumatol. 2020;2:e779–90.

11. Payne V, Kam PCA. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004;59:695–703.

12. Lowenstein CJ, Solomon SD. Severe COVID-19 is a microvascular disease. Circulation. 2020;142:1609–11.

13. Tan BK, Mainbourg S, Friggetti A, Bertolletti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76:970–9.

14. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29:17–24.

15. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360.

16. Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, et al. Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium. Nat Rev Cardiol. 2022;19:1–21.

17. Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020;18:2215–9.

18. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCTT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136:489–500.

19. Weisel JW. Fibrinogen and fibrin. Cambridge, Massachusetts (USA): Academic Press Inc; 2005. p. 247–99.

20. Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 Infection. J Am Coll Surg. 2020;231:193–203.

21. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28:e72.

22. vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3(8):1879–83.

23. Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep. 2021;11:1580.

24. Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol. 2010;55:2701–9.

25. Chandler WL, Alessi MC, Ailauld MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Circulation. 1997;96:761–8.

26. Ragusa R, Basta G, Del Turco S, Caselli C. A possible role for ST2 as prognostic biomarker for COVID-19. Vasc Pharmacol. 2021;138:106857.

27. Meyer MC, Creer MH, McHowat J. Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium. J Physiol Cell Physiol. 2005;289:C1485–91.

28. Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol. 2000;165:3154–61.
weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis. 2021;24:505–17.

30. Mancini I, Baronciani L, Antoni A, Colpani P, Biganzoli M, Cozzi G, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19:513–21.

31. Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (Micro)thrombosis. Semin Thromb Hemost. 2021;47:400–18.

32. Coenen DM, Mastenbroek TG, Cosemans JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 2017;130:2819–28.

33. Seth R, McKinnon TAJ, Zhang XF. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. Am J Physiol Heart Circ Physiol. 2021;322:H87–93.

34. Mussbacher M, Schrottmair WC, Salzmann M, Brostjan C, Schmid JA, Starlinger P, et al. Optimized plasma preparation is essential to monitor platelet-stored molecules in humans. PLoS One. 2017;12:e0188921.

35. Zaid Y, Puhm F, Allaesys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127:1404–18.

36. Prechel MM, Walenga JM. Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of hepatic induced thrombocytopenia. Thromb J. 2013;11:7.

37. Ward SE, Curley GF, Lavin M, Fogarty H, Karampini E, McEvoy NL, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192:714–9.

38. Fenyves BG, Mehta A, Kays KR, Beakes C, Margolin J, Team MC-19 C& P, et al. Plasma P-selectin is an early marker of thromboembolism in COVID-19. Am J Hematol. 2021;96:E468–71.

39. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136:1330–41.

40. Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ Res. 2020;127:945–7.

41. Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22:77–84.

42. Wang J, Hajizadeh N, Moore EE, Wang J, Hajizadeh N, Biffi WL, et al. Study of alteplase for respiratory failure in SARS-CoV-2 COVID-19 (STARS): a vanguard multicenter, rapidly adaptive, pragmatic, randomized, controlled trial. SSRN Electron J. 2021;161:710–27.

43. Verstraete M, Bournaneau H, de Cock F, Van de Werf F, Col- len D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther. 1985;235:506–12.

44. Abdelaaal Ahmed Mahmoud A, Mahmoud HE, Mahran MA, Khaled M. streptokinase versus unfractionated heparin nebulization in patients with severe acute respiratory distress syndrome (ARDS): a randomized controlled trial with observational controls, J Cardiothorac Vasc Anesth. 2020;34:436–43.

45. Sillen M, Miyata T, Vaughan DE, Strelkov SV, Decker CP, Krishnamurthy G, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem. 2004;47:3491–4.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.